Uncategorized

Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy

Published

on

Boston biotech Ensoma is doubling down on its lead gene therapy for a rare immune disease, laying off another round of employees after previously halving its workforce last November.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version